Abstract
Severe sepsis is a complex condition with mortality rates ranging from 30 to 50% in spite of advances in critical care. Xigris (drotrecogin alfa (activated)) is associated with an absolute reduction in the risk of death of 6.1% and was granted European Union marketing authorization in August 2002.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anti-Infective Agents / therapeutic use*
-
Humans
-
Protein C / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Recombinant Proteins / therapeutic use*
-
Sepsis / drug therapy*
-
Treatment Outcome
Substances
-
Anti-Infective Agents
-
Protein C
-
Recombinant Proteins
-
drotrecogin alfa activated